Help managing GLP-1 associated side effects Speak to a health care provider about managing drug side effects and to rule out any other possible causes
In a retrospective study GLP-1 agonists have been shown to be associated with lower rates of hepatic decompensations compared to other glycemic agents, although more prospective data is needed
Clinical Trial Evidence for Wegovy Wegovy approval was supported by large, randomized clinical trials, including the STEP 1 study: 1,961 adults with obesity or overweight plus weight-related health conditions 68-week study duration Average weight loss of approximately 14.9% of body weight 86% of participants lost at least 5% of body weight 69% lost at least 10% 50% lost at least 15% Participants followed reduced-calorie diets and increased physical activity Before receiving FDA approval, GLP-1 medications completed Phase I, Phase II, and Phase III trials
During periods when brand-name tirzepatide has been on the FDA shortage list, compounding has been legally permitted
Some find switching between medications changes their dry mouth severity, while others notice no difference
Both Wegovy and Ozempic contain semaglutide as the active ingredient
